StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Tezspire (tezepelumab by Quarter

Tezspire (tezepelumab — direct product sales) — Established RoW product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Tezspire (tezepelumab: $41M in Q2 2026, up 32.3% from a year earlier. That is the highest of the 15 quarters on record here.

Latest, Q2 2026
41
Period ended Jun 30, 2026
Change on a year earlier
+32.3%
31 in Q2 2025
History
15 quarters
Since Q4 2022
Sources
15
Documents cited below

Where the Q2 2026 figure comes from

“|| Tezspire | | 172 | | 54 | | 51 | | - | | - | | 24 | | n/m | | n/m | | 107 | | 49 | | 42 | | 41 | | 33 | | 41”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTezspire (tezepelumab — direct product sales) — Established RoW product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202641+32.3%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202634+47.8%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 202535+40.0%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202532+45.5%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202531+63.2%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202523+64.3%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202425+78.6%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202422+120.0%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202419+137.5%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202414+250.0%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202314+600.0%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202310–Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 20238–Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 20234–Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 20222–Form 6-K FY2022Q4 Earnings Release ↗

Breakdown

What makes up tezspire (tezepelumab

Cite this data

StockData. (2026). AstraZeneca Tezspire (tezepelumab ($M), quarterly Q4 2022–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-tezspire-erow

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.